Cargando…
Design, synthesis, in vitro biological assessment and molecular modeling insights for novel 3-(naphthalen-1-yl)-4,5-dihydropyrazoles as anticancer agents with potential EGFR inhibitory activity
Currently, the humanity is in a fierce battle against various health-related challenges especially those associated with human malignancies. This created the urge to develop potent and selective inhibitors for tumor cells through targeting specific oncogenic proteins possessing crucial roles in canc...
Autores principales: | Eldehna, Wagdy M., El Hassab, Mahmoud A., Elsayed, Zainab M., Al-Warhi, Tarfah, Elkady, Hazem, Abo-Ashour, Mahmoud F., Abourehab, Mohammed A. S., Eissa, Ibrahim H., Abdel-Aziz, Hatem A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9329325/ https://www.ncbi.nlm.nih.gov/pubmed/35896557 http://dx.doi.org/10.1038/s41598-022-15050-8 |
Ejemplares similares
-
Novel 2-(5-Aryl-4,5-Dihydropyrazol-1-yl)thiazol-4-One as EGFR Inhibitors: Synthesis, Biological Assessment and Molecular Docking Insights
por: Al-Warhi, Tarfah, et al.
Publicado: (2022) -
Identification of a New Potential SARS-COV-2 RNA-Dependent RNA Polymerase Inhibitor via Combining Fragment-Based Drug Design, Docking, Molecular Dynamics, and MM-PBSA Calculations
por: El Hassab, Mahmoud A., et al.
Publicado: (2020) -
1-Benzyl-5-bromo-3-hydrazonoindolin-2-ones as Novel Anticancer Agents: Synthesis, Biological Evaluation and Molecular Modeling Insights
por: Al-Warhi, Tarfah, et al.
Publicado: (2023) -
Development of novel isatin–nicotinohydrazide hybrids with potent activity against susceptible/resistant Mycobacterium tuberculosis and bronchitis causing–bacteria
por: Elsayed, Zainab M., et al.
Publicado: (2021) -
Enaminone-based carboxylic acids as novel non-classical carbonic anhydrases inhibitors: design, synthesis and in vitro biological assessment
por: Abo-Ashour, Mahmoud F., et al.
Publicado: (2022)